Everything below concerns c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Central nervous system medicines Immunology/Allergy medicines Nephrology medicines ESPO / NESP / Aranesp (darbepoetin alfa) REGPARA (cincalcet) Oncology medicines ABSTRAL (fentanyl citrate) GRAN / Peglasta / Neulasta (pegfilgrastim) LEUNASE (asparaginase) Mitomycin-C SANCUSO (granisetron) Diagnostics In vitro diagnostic reagents, analyzers and companion diagnostics
=== Hemolytic effect === Guanacastepene A also exhibits a significant toxic side effect in that it possesses pronounced hemolytic activity, which leads to the lysis of erythrocytes (human red blood cells). The strongest hemolytic effect was observed in laboratory tests at concentrations between 8 and 32 µg/ml. However, this effect diminishes at very high concentrations (above 64 µg/ml) as well as at very low concentrations (below 8 µg/ml). The mechanism of cell membrane damage is not selective enough for bacteria; eukaryotic cell membranes are also affected by the damaging effect of Guanacastepene A.
=== Receptors === Even though much weaker than glycine (and, thus, with a debated role as a physiological transmitter), β-alanine is an agonist next in activity to the cognate ligand glycine itself, for strychnine-sensitive inhibitory glycine receptors (GlyRs) (the agonist order: glycine ≫ β-alanine > taurine ≫ alanine, L-serine > proline). β-alanine has five known receptor sites, including GABA-A, GABA-C a co-agonist site (with glycine) on NMDA receptors, the aforementioned GlyR site, and blockade of GAT protein-mediated glial GABA uptake, making it a putative "small molecule neurotransmitter."
Sources: en.wikipedia.org
=== Commercialization === With an alcohol content under 0.5%, kombucha is not federally regulated in the U.S. Commercially bottled kombucha became available in the late 1990s. In 2010, elevated alcohol levels were found in many bottled kombucha products, leading retailers including Whole Foods to pull the drinks from store shelves temporarily. In response, kombucha suppliers reformulated their products to have lower alcohol levels. Again prior to 2015, some commercially available kombucha brands were found to contain alcohol content exceeding the 0.5% threshold, sparking the development of new testing methods. By 2014, US sales of bottled kombucha were $400 million, $350 million of which was by Millennium Products, Inc. which sells GT's Kombucha. In 2014, several companies that make and sell kombucha formed a trade organization, Kombucha Brewers International. In 2016, PepsiCo purchased kombucha maker KeVita for approximately $200 million. In the US, sales of kombucha and other fermented drinks rose by 37 percent in 2017. Beer companies like Full Sail Brewing Company and Molson Coors Beverage Company produce kombucha by themselves or via subsidiaries. As of 2021, the drink had some popularity in India's National Capital Region, partly due to its success in the west. With rising popularity in developed countries in the early 21st century, kombucha sales increased after it was marketed as an alternative to beer and other alcoholic drinks in restaurants and pubs.
People with high levels of factor VIII are at increased risk for deep vein thrombosis and pulmonary embolism. Copper is a required cofactor for factor VIII and copper deficiency is known to increase the activity of factor VIII. Factor VIII is on the World Health Organization's List of Essential Medicines.
absorption 1. The physical or chemical process by which a substance in one state becomes incorporated into and retained by another substance of a different state. Absorption differs from adsorption in that the first substance permeates the entire bulk of the second substance, rather than just adhering to the surface. 2. The process by which matter (typically electrons bound in atoms) takes up the energy of electromagnetic radiation and transforms it into any of various types of internal energy, such as thermal energy. This type of absorption is the principle on which spectrophotometry is based.
For services to the community in Rugby, Warwickshire. Margaret Sandra Myers. For services to the community in Sheffield, South Yorkshire. David Mynott. Volunteer, Torfaen Dementia Group. For services to People with Dementia and their Carers. Moez Kass Amali Nathu. Chief Executive, Peterborough Asylum and Refugee Community Association. For services to Refugees and Asylum Seekers in Peterborough. Robert Thomson Nellies. President, Falkland Cricket Club. For services to Cricket and to the community in Fife. Elyn Catherine Neville. For charitable services to Cancer Patients and to Cancer Services in Pembrokeshire. Margaret Alice Newell. Lately Office Manager, Privy Council Office. For Public Service, particularly during the Accession Council. Matthanee Nilavongse. For services to the community in Todmorden, West Yorkshire. William Ellis Nixon. Honorary Secretary, Social Enterprise UK. For services to Young People in the West Midlands. Uzoamaka Louisa Nwokolo. Lately Executive Officer, Department for Transport. For services to Young People. Diana Violet O'Grady. For services to the community in Arreton, Isle of Wight. Samuel Jozef Oldroyd. Chief Executive Officer, JADE Youth and Community. For services to Young People and Families in Rother Valley, South Yorkshire. Clive John Owen. Vice Chair, Aberavon Green Stars Rugby Football Club. For charitable services to Young People and to the community in Aberavon, West Glamorgan. Diane Oxley. For services to Young People and to the community in Thurcroft, South Yorkshire. Tracie Ann Pal.
Sources: en.wikipedia.org
=== MSEIRS model === An MSEIRS model is similar to the MSEIR, but the immunity in the R class would be temporary, so that individuals would regain their susceptibility when the temporary immunity ended.
A fault on a power sub-transmission feeder causes a power shortage in the southern Far North District that affects 23,000 homes and businesses. 7 November – Local authorities in the Clutha District and Southland Region lift local states of emergency caused by the October 2025 New Zealand storms. 8 November – A wildfire breaks out in Tongariro National Park, engulfing 2,500 hectares and leading to the evacuation of campers and the closure of a nearby highway. 9 November: The wildfire in Tongariro National Park engulfs 2,500 hectares, leading to the evacuation of Whakapapa Village. Firefighters manage to contain 20% of the fire. Te Pāti Māori's national council votes overnight to expel MPs Mariameno Kapa-Kingi and Tākuta Ferris following several weeks of internal conflict. The decision is confirmed by the party's leadership the following day. The New Zealand government extends its suspension of NZ$29.8 million worth of funding to the Cook Islands over the next two financial years in response to the Cook Islands government signing several partnership agreements with China in February 2025. 10 November: The wildfire in the Tongariro National Park subsides due to rainfall and the efforts of firefighters to contain the blaze. Residents of Whakapapa Village are allowed to return. An estimated 3,000 hectares have been damaged by the wildfire. The contactless fare payment system Motu Move is launched on public buses and the ferry in Christchurch.
In response, Cottrell went on to establish an independent nonprofit organization on 26 February 1912 — the Research Corporation for Science Advancement — not only to manage his own patents, but to "contract with various universities, industry workers, and unattached inventors in order to manage their patents", with the profits used to fund research, regardless of the applicant's university. In 1925, Harry Steenbock, a professor of biochemistry at the University of Wisconsin–Madison, offered to assign his thyroxine patent rights (HS.1) to the university. The university's Regents declined Steenbock's offer. In response, the Wisconsin Alumni Research Foundation (WARF), an independent University technology transfer office, was created to manage Steenbok's patent; and, by 2023, WARF had gone on to manage more than 4,200 patents (with 2,200 patents still active). For Robertson, the need for appropriate buildings, laboratories, supplies, and equipment to be funded for research was always at least as important as the funding of any individual researcher. In 1917, in a precedent-setting action, Robertson proposed assigning his patent rights to the University of California (EN.1; SC.1) (i.e., rather than Cottrell's non-specific Research Corporation) specifically to support medical research at the University of California.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.